Related Experiment Video
Updated: Aug 14, 2026

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
Published on: May 3, 2017
Glutamatergic influences on the basal ganglia
1Department of Neurology, Emory University, Atlanta, Georgia 30322, USA.
Abstract:
Glutamate is the predominant excitatory neurotransmitter of the basal ganglia, where it acts on ionotropic and metabotropic receptors. In the best studied of the basal ganglia disorders, Parkinson's disease, there is compelling evidence that the activities of glutamatergic pathways are altered. Of particular importance, the glutamatergic subthalamic nucleus becomes overactive. Pharmacologic blockade of subthalamic neurotransmission has antiparkinsonian symptomatic effects and may also help to protect the remaining dopamine neurons of the substantia nigra from excitotoxic neurodegeneration. Development of drugs to manipulate the glutamatergic system with appropriate pharmacologic and anatomic selectivity is likely to dramatically improve our ability to treat disorders of the basal ganglia.
More Related Videos
Related Concept Videos
Glial Cells
Excitatory and Inhibitory Effects of Neurotransmitters
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Diencephalon: Anatomical Regions
Diencephalon: Thalamus and Information Relay

